Denis Riendeau
TransCanada (Canada)(CA)Merck Canada Inc. (Canada)(CA)
Publications by Year
Research Areas
Inflammatory mediators and NSAID effects, Estrogen and related hormone effects, Eicosanoids and Hypertension Pharmacology, Synthesis and biological activity, Asthma and respiratory diseases
Most-Cited Works
- → The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K(2008)470 cited
- → Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts(1996)465 cited
- → Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2(2001)457 cited
- → The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor(1999)427 cited
- → L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor(1989)328 cited
- → Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model(1999)326 cited